This present study describes the antitumor efficacy of HER2-DC1 i.t. combined with anti-HER2 antibodies treatment in three different HER2pos BC models such as the rat HER2 expressing TUBO tumor model, BALB-HER2 transgenic spontaneous tumor model and clinically relevant human HER2 expressing CT26 tumor model. This evidence concerns the gene ERBB2 and neoplasm.